Previous to joining Nox, Dr. Thorndike was with Pear Therapeutics, where she served as Vice President, Medical Affairs and Discovery, and led the clinical effort for FDA authorization of Somryst, the first FDA-cleared prescription digital therapeutic for chronic insomnia. Prior to Pear Therapeutics, Dr. Thorndike was Co-founder and Chief Science Officer of BeHealth Solutions, a start-up focused on disseminating evidence-based digital therapeutics, and has also served as Assistant Professor, Department of Psychiatry and Neurobehavioral Sciences at University of Virginia Health System.